RNS23 Feb 2026 07:23
Acquisition of Southern Cross Diagnostics
Paris, France, and Manchester, UK - 23 February 2026 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it has conditionally agreed to acquire, via its wholly owned subsidiary, Novacyt Holdings UK Limited ("Novacyt UK"), the entire issued share capital of Southern Cross Diagnostics Pty Ltd ("SCD" or "Southern Cross Diagnostics"), a profitable distributor of diagnostic and life science products, for an initial cash consideration of AUD$8.5m (equivalent to approximately £4.4m or €5.1m)* ("Acquisition"). SCD is based in Sydney, Australia and has been a distribution partner for Novacyt subsidiary Yourgene Health since its acquisition of Elucigene Diagnostics in 2019.